PE20131062A1 - Uso de hmgb1 como marcador biologico de afecciones intestinales inflamatorias, metodo no invasivo para su deteccion en muestras fecales y kit para su realizacion - Google Patents
Uso de hmgb1 como marcador biologico de afecciones intestinales inflamatorias, metodo no invasivo para su deteccion en muestras fecales y kit para su realizacionInfo
- Publication number
- PE20131062A1 PE20131062A1 PE2013000131A PE2013000131A PE20131062A1 PE 20131062 A1 PE20131062 A1 PE 20131062A1 PE 2013000131 A PE2013000131 A PE 2013000131A PE 2013000131 A PE2013000131 A PE 2013000131A PE 20131062 A1 PE20131062 A1 PE 20131062A1
- Authority
- PE
- Peru
- Prior art keywords
- hmgb1
- detection
- kit
- realization
- fecal samples
- Prior art date
Links
- 230000002550 fecal effect Effects 0.000 title abstract 4
- 102000055207 HMGB1 Human genes 0.000 title abstract 3
- 108700010013 HMGB1 Proteins 0.000 title abstract 3
- 238000001514 detection method Methods 0.000 title abstract 3
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 title abstract 2
- 101150021904 HMGB1 gene Proteins 0.000 title abstract 2
- 239000000090 biomarker Substances 0.000 title 1
- 230000002757 inflammatory effect Effects 0.000 title 1
- 230000000968 intestinal effect Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 238000005119 centrifugation Methods 0.000 abstract 1
- 238000011156 evaluation Methods 0.000 abstract 1
- 239000000284 extract Substances 0.000 abstract 1
- 238000000605 extraction Methods 0.000 abstract 1
- 239000011536 extraction buffer Substances 0.000 abstract 1
- 238000000265 homogenisation Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- 238000005303 weighing Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6875—Nucleoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITRM2010A000442A IT1406051B1 (it) | 2010-08-05 | 2010-08-05 | Uso di hmgb1 come marcatore biologico di infiammazione intestinale umana, metodo non invasivo per la sua rilevazione in campioni fecali e kit relativo. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20131062A1 true PE20131062A1 (es) | 2013-10-16 |
Family
ID=43739596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2013000131A PE20131062A1 (es) | 2010-08-05 | 2011-08-01 | Uso de hmgb1 como marcador biologico de afecciones intestinales inflamatorias, metodo no invasivo para su deteccion en muestras fecales y kit para su realizacion |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20130137123A1 (https=) |
| EP (1) | EP2601525A1 (https=) |
| JP (1) | JP2013534313A (https=) |
| CN (1) | CN103069276A (https=) |
| AU (1) | AU2011287193B2 (https=) |
| BR (1) | BR112013002145A2 (https=) |
| CA (1) | CA2807107C (https=) |
| CL (1) | CL2013000223A1 (https=) |
| EA (1) | EA201390197A1 (https=) |
| IL (1) | IL223845A (https=) |
| IT (1) | IT1406051B1 (https=) |
| MX (1) | MX2013001327A (https=) |
| PE (1) | PE20131062A1 (https=) |
| WO (1) | WO2012017466A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015067913A1 (en) | 2013-11-07 | 2015-05-14 | Diagnodus Limited | Biomarkers |
| DK2968443T3 (da) | 2013-03-15 | 2021-12-06 | Protagonist Therapeutics Inc | Hepcidinanaloger og anvendelser deraf |
| PT3143037T (pt) | 2014-05-16 | 2021-09-24 | Protagonist Therapeutics Inc | Antagonistas peptídicos tioéter de integrina alfa4beta7 |
| US9624268B2 (en) | 2014-07-17 | 2017-04-18 | Protagonist Therapeutics, Inc. | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| US20190002503A1 (en) | 2015-12-30 | 2019-01-03 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| US20200064357A1 (en) * | 2016-11-09 | 2020-02-27 | Protagonist Therapeutics, Inc. | Methods for determining and monitoring gastrointestinal inflammation |
| PL3622082T3 (pl) | 2017-05-12 | 2023-07-31 | Evonik Operations Gmbh | Sposób wykrywania chorób wywołanych przez C. perfringens w stadzie ptaków |
| IT201700083044A1 (it) | 2017-07-20 | 2019-01-20 | Laura Stronati | “uso della gelsolina come marcatore diagnostico e prognostico delle malattie infiammatorie intestinali” |
| IT201700083055A1 (it) | 2017-07-20 | 2019-01-20 | Laura Stronati | “uso della proteina inibitore 2 della dissociazione di rho gdp come marcatore diagnostico e prognostico delle malattie infiammatorie intestinali” |
| EP3749345A4 (en) | 2018-02-08 | 2022-04-06 | Protagonist Therapeutics, Inc. | CONJUGATED HEPCIDIN MIMETICS |
| US12031991B2 (en) * | 2018-03-02 | 2024-07-09 | Evonik Operations Gmbh | In vitro method for detecting intestinal barrier failure in animals |
| CN109030817A (zh) * | 2018-07-04 | 2018-12-18 | 长沙都正医学检验有限责任公司 | Hmgb1检测试剂盒及其制备方法 |
| TW202019948A (zh) | 2018-07-12 | 2020-06-01 | 美商領導醫療有限公司 | 介白素-23受體之肽抑制劑及其治療發炎疾病之用途 |
| DK3894863T3 (en) | 2018-12-14 | 2023-02-20 | Evonik Operations Gmbh | In vitro-fremgangsmåde til påvisning af aviær intestinal dysbiose |
| US11684653B2 (en) * | 2019-03-06 | 2023-06-27 | The Cleveland Clinic Foundation | Compositions and method for reducing virulence of microorganisms |
| HRP20250769T1 (hr) | 2020-01-15 | 2025-08-29 | Janssen Biotech, Inc. | Peptidni inhibitori receptora za interleukin-23 i njihova uporaba u liječenju upalnih bolesti |
| AU2021209086A1 (en) | 2020-01-15 | 2022-08-04 | Janssen Biotech, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| AU2021383828A1 (en) | 2020-11-20 | 2023-07-06 | Janssen Pharmaceutica Nv | Compositions of peptide inhibitors of interleukin-23 receptor |
| WO2023288019A2 (en) | 2021-07-14 | 2023-01-19 | Janssen Biotech, Inc. | Lipidated peptide inhibitors of interleukin-23 receptor |
| CN116973572B (zh) * | 2023-06-02 | 2025-03-07 | 东南大学附属中大医院 | 基于血、粪便铁蛋白检测评估肠屏障损伤严重程度的方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6822078B2 (en) * | 1996-07-17 | 2004-11-23 | Kaneka Corp. | Diagnostic drugs for autoimmune diseases |
| US6355623B2 (en) * | 1998-09-24 | 2002-03-12 | Hopital-Sainte-Justine | Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage |
| US6303321B1 (en) * | 1999-02-11 | 2001-10-16 | North Shore-Long Island Jewish Research Institute | Methods for diagnosing sepsis |
| US7700307B2 (en) * | 2003-03-08 | 2010-04-20 | Auvation Limited | Mitochondrial stress-70 protein markers for colorectal cancer |
| US7585504B2 (en) * | 2004-10-22 | 2009-09-08 | Medimmune, Llc | High affinity antibodies against HMGB1 and methods of use thereof |
| US20090297546A1 (en) * | 2006-12-20 | 2009-12-03 | Shino-Test Corporation | Avian-derived antibody capable of binding specifically to human hmgb1, immunological determination method for human hmgb1, and immunological determination reagent for human hmgb1 |
| EA201000131A1 (ru) * | 2007-08-02 | 2010-08-30 | АйЭсЭс ИММЬЮН СИСТЕМ СТИМУЛЕЙШН АБ | Диагностика, определение стадии и мониторинг воспалительного заболевания кишечника |
| US7879553B2 (en) * | 2008-03-14 | 2011-02-01 | Exagen Diagnostics, Inc. | Biomarkers for inflammatory bowel disease and irritable bowel syndrome |
-
2010
- 2010-08-05 IT ITRM2010A000442A patent/IT1406051B1/it active
-
2011
- 2011-08-01 BR BR112013002145A patent/BR112013002145A2/pt not_active IP Right Cessation
- 2011-08-01 WO PCT/IT2011/000276 patent/WO2012017466A1/en not_active Ceased
- 2011-08-01 EP EP11754539.2A patent/EP2601525A1/en not_active Withdrawn
- 2011-08-01 CA CA2807107A patent/CA2807107C/en not_active Expired - Fee Related
- 2011-08-01 MX MX2013001327A patent/MX2013001327A/es unknown
- 2011-08-01 US US13/814,294 patent/US20130137123A1/en not_active Abandoned
- 2011-08-01 JP JP2013522346A patent/JP2013534313A/ja active Pending
- 2011-08-01 CN CN2011800327624A patent/CN103069276A/zh active Pending
- 2011-08-01 EA EA201390197A patent/EA201390197A1/ru unknown
- 2011-08-01 PE PE2013000131A patent/PE20131062A1/es not_active Application Discontinuation
- 2011-08-01 AU AU2011287193A patent/AU2011287193B2/en not_active Ceased
-
2012
- 2012-12-24 IL IL223845A patent/IL223845A/en active IP Right Grant
-
2013
- 2013-01-23 CL CL2013000223A patent/CL2013000223A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011287193B2 (en) | 2015-08-13 |
| WO2012017466A8 (en) | 2013-07-11 |
| EA201390197A1 (ru) | 2013-06-28 |
| JP2013534313A (ja) | 2013-09-02 |
| CN103069276A (zh) | 2013-04-24 |
| AU2011287193A1 (en) | 2013-06-13 |
| ITRM20100442A1 (it) | 2012-02-06 |
| WO2012017466A1 (en) | 2012-02-09 |
| IT1406051B1 (it) | 2014-02-06 |
| MX2013001327A (es) | 2013-03-08 |
| CA2807107C (en) | 2017-01-03 |
| CL2013000223A1 (es) | 2014-03-28 |
| CA2807107A1 (en) | 2012-02-09 |
| EP2601525A1 (en) | 2013-06-12 |
| BR112013002145A2 (pt) | 2016-05-24 |
| US20130137123A1 (en) | 2013-05-30 |
| IL223845A (en) | 2016-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20131062A1 (es) | Uso de hmgb1 como marcador biologico de afecciones intestinales inflamatorias, metodo no invasivo para su deteccion en muestras fecales y kit para su realizacion | |
| BRPI0915619A2 (pt) | métodos para determinar uma probabilidade de que um sujeito tenha contribuído com material genético para amostra de teste de material genético, para caracterizar amostra de teste de material genético e para determinar se uma pessoa de interesse contribuiu com material genético para uma amostra de teste de material genético, kit para análise de amostra de teste de material genético e sistema para determinar se um sujeito contribuiu com material genético para uma amostra | |
| PH12020551371A1 (en) | Assays to detect neurodegeneration | |
| BRPI1007867B8 (pt) | anticorpo recombinante ou fragmento de ligação ao antígeno do mesmo, composição farmacêutica e kit compreendendo o referido anticorpo, métodos de detecção de antígeno de troponina i em uma amostra de teste e métodos in vitro de diagnóstico de síndrome coronariana aguda ou infarto do miocárdio em um paciente | |
| CO2019008675A2 (es) | Anticuerpos anti-lag3 radiomarcados para la obtención de imágenes mediante inmuno-pet | |
| BR112015026248A2 (pt) | dispositivo de coleta de fluido biológico e sistema de separação e teste de fluido biológico | |
| BR112015026242A2 (pt) | dispositivo de coleta de fluido biológico e sistema de separação e testagem de fluido biológico | |
| EP4273551A3 (en) | Multiplexed total antibody and antibody-conjugated drug quantification assay | |
| PE20141450A1 (es) | Ensayo de lisiloxidasa-homologo 2 y metodos de uso del mismo | |
| BR112012016119B1 (pt) | método de detecção de células em uma amostra, dispositivo unitário de preparação e detecção de amostra e kit | |
| BR112016004320A2 (pt) | biossensor, sistema, kit, métodos de determinação ou de identificação e de quantificação de uma concentração de amônia ou íon amônio, de diagnóstico de uma doença metabólica em um sujeito, de determinação da resposta do paciente a uma terapia, de fabricação de um biossensor, de um sistema ou de qualquer tira de teste e de detecção da presença, ausência, ou quantidade de aminoácidos em uma amostra, e, tira de teste | |
| BRPI0720707A2 (pt) | Sistema de teste para uso com um tampão para testar a presença de moléculas alvo de um ou mais tipos de alvo em uma amostra de teste biológico; sistema de teste para testar a presença de moléculas alvo de um ou mais tipos de alvo em uma amostra de teste biológico; e método de focalização de moléculas para facilitar um teste da presença de moléculas alvo de um ou mais tipos de alvo de uma amostra de teste biológico. | |
| BR112015026246A2 (pt) | dispositivo de transferência de coleta de sangue e separação de sangue e sistema de teste | |
| AR053948A1 (es) | Deteccion de un antigeno diana independientemente de la presencia o ausencia de un anticuerpo terapeutico correspondiente | |
| AR083259A1 (es) | Cuantificacion y caracterizacion de los alergenos | |
| ES2684758T3 (es) | Procedimiento para diagnosticar fibrosis hepática | |
| BR112014031958A2 (pt) | bag3 como marcador de tecido e soro bioquímico | |
| EA201400356A1 (ru) | Иммуноанализ для обнаружения антибиотиков | |
| CY1121482T1 (el) | Ευαισθητη πολυπλεκτικη ανοσοδοκιμασια για τους διαλυτους υποδοχεις των αυξητικων παραγοντων των ινοβλαστων | |
| Le Gall‐Lanotto et al. | Road‐traffic‐related air pollution contributes to skin barrier alteration and growth defect of sensory neurons | |
| Fernández-Niño et al. | Agreement of the Kato-Katz test established by the WHO with samples fixed with sodium acetate analyzed at 6 months to diagnose intestinal geohelminthes | |
| PE20121648A1 (es) | Procedimiento de identificacion de animales vacunados frente a brucella | |
| BR112012027535A2 (pt) | método para a detecção da susceptibilidade em desenvolver efeitos colaterais adversos relacionados com bioimplantes | |
| ZHAO et al. | Detection of BRAF in the synovial fluid and its clinical significance in rheumatoid arthritis | |
| WANG et al. | Clinical value of urine heparin-binding protein in the diagnosis of urinary tract infection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |